Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Editas Medicine (NQ: EDIT ) 2.900 -0.120 (-3.97%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Editas Medicine < Previous 1 2 3 4 5 6 7 8 9 Next > Expert Outlook: Editas Medicine Through The Eyes Of 7 Analysts October 23, 2024 Via Benzinga Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. September 26, 2024 Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. Via Investor's Business Daily Where Editas Medicine Stands With Analysts September 17, 2024 Via Benzinga Looking for Stock Bargains With Room to Run? Try This. September 11, 2024 Investing tips from Bill Mann, The Motley Fool's director of small-cap research. Via The Motley Fool Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday August 08, 2024 Via Benzinga Unveiling 5 Analyst Insights On Editas Medicine June 18, 2024 Via Benzinga The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts May 30, 2024 Via Benzinga The Latest Analyst Ratings For Editas Medicine February 29, 2024 Via Benzinga 3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition July 17, 2024 Explore gene-editing stocks with potential to become multibaggers as the industry advances in treating genetic disorders. Via InvestorPlace 3 Profitable CRISPR Stocks Earning Analysts’ Praise July 09, 2024 Revolutionary gene-editing technologies provide promise for investors seeking the most profitable CRISPR stocks today and in the future. Via InvestorPlace The 3 Best Gene Editing Stocks to Buy in July 2024 July 08, 2024 Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. Via InvestorPlace Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich June 26, 2024 Gene editing is a game-changer, creating substantial opportunities for some of the leading gene editing stocks. Via InvestorPlace 3 Gene Editing Stocks That Could Make Your Grandchildren Rich June 25, 2024 Explore gene-editing stocks with long-term growth potential, offering innovative solutions to previously untreatable conditions. Via InvestorPlace Earnings Outlook For Editas Medicine February 27, 2024 Via Benzinga Overlooked and Undervalued: 3 Stocks With Jaw-Dropping Upside Potential May 30, 2024 Invest in these undervalued stocks poised for long-term growth as Wall Street shifts focus to broader market gains. Via InvestorPlace 1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5? May 09, 2024 The company has great potential if and when it enters the commercial stage. Via The Motley Fool EDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024 May 08, 2024 EDIT stock results show that Editas Medicine missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. Via InvestorPlace 1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right. March 07, 2024 The company now has a chance to get its lead program out the door a bit sooner. Via The Motley Fool 1 Beaten-Down Stock With 55% Upside, According to Wall Street March 04, 2024 The biotech has bounced back some in the past year. Via The Motley Fool Why Editas Medicine Stock Soared as Much as 42% Higher This Week March 02, 2024 The clinical-stage genome editing company dropped a couple of important announcements for shareholders. Via The Motley Fool Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session February 28, 2024 Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results. Via Benzinga TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares? February 28, 2024 The company reported in-line sales for the fourth quarter, but shares soared by double digits. Via Investor's Business Daily Advance Auto Parts Reports Q4 Results, Joins B&G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On Wednesday February 28, 2024 U.S. stocks were lower, with the Dow Jones index falling around 100 points on Wednesday. Via Benzinga Topics Stocks Exposures US Equities 2 Under-the-Radar Stocks With Incredible Upside Potential January 28, 2024 It's also important to consider their downsides. Via The Motley Fool Could Editas Medicine Become the Next CRISPR Therapeutics? January 21, 2024 The similarities between the pair are striking, but it might not be enough. Via The Motley Fool 7 Mighty Healthcare Stocks Changing the Game of Medicine January 17, 2024 Thanks to the permanent relevance of medical innovations, investors ought to consider looking at these healthcare stocks. Via InvestorPlace Down 88%, Could Editas Medicine Be a Good Investment Now? January 15, 2024 The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles. Via The Motley Fool 3 Stocks to Buy in the Booming Field of Gene Editing January 11, 2024 As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains. Via InvestorPlace Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics January 08, 2024 These two are at very different stages of the clinical trials process. Via The Motley Fool Editas Just Caught a Break Thanks to Vertex Pharmaceuticals December 23, 2023 Editas isn't out of the woods yet, but it's better off than before. Via The Motley Fool < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
